<DOC>
	<DOC>NCT00431041</DOC>
	<brief_summary>The purpose of this study is to compare the safety and efficacy of solifenacin with oxybutynin immediate-release (IR) for the treatment of overactive bladder (OAB).</brief_summary>
	<brief_title>Study to Compare the Safety and Efficacy of Solifenacin With Oxybutynin for the Treatment of Overactive Bladder (VECTOR)</brief_title>
	<detailed_description>This study is a prospective randomized, double-blind, double-dummy, multicentre, 2-arm (1 Active, Active Control) comparative parallel group study to compare the safety and efficacy of solifenacin with oxybutynin immediate-release (IR) for the treatment of overactive bladder (OAB).</detailed_description>
	<mesh_term>Urinary Bladder, Overactive</mesh_term>
	<mesh_term>Solifenacin Succinate</mesh_term>
	<mesh_term>Oxybutynin</mesh_term>
	<mesh_term>Mandelic Acids</mesh_term>
	<criteria>Adults 18 years and older. Overactive bladder symptoms for greater than or equal to 3 months and as documented in a 3day patient diary following screening and preceding baseline visit: &gt; 1 urge episodes/24 hours (average); greater than or equal to 8 micturitions/24 hours (average) Urinary tract infection, chronic inflammation such as interstitial cystitis and bladder stones Clinically significant outflow obstruction Uncontrolled narrow angle glaucoma, urinary, or gastric retention Severe renal or hepatic impairment Chronic severe constipation or history of diagnosed GI obstructive disease Significant stress incontinence or mixed stress/urge incontinence where stress is the predominant factor Diagnosis or history of neurogenic bladder History of bladder or pelvic cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>Solifenacin succinate</keyword>
	<keyword>Oxybutynin immediate release</keyword>
	<keyword>Xerostomia</keyword>
	<keyword>Overactive bladder</keyword>
</DOC>